

The Cancer Research Institute (CRI) is proud to highlight selected sessions and presentations during SITC 2025 with a focus on:

- Microbiome-immune Crosstalk
- Biomarkers and Neoadjuvant Immunotherapy
- Immune Regulation and TME Dynamics
- Cancer Immunoprevention
- Metabolic Pathways and Cell Therapy Innovation
- Immune Targets from the Dark Genome



FRIDAY, NOVEMBER 7

| TIME | LOCATION | SESSION & TALK TITLE | SPEAKER |
|---------|-------------------------|--|--|
| 8:25 AM | Potomac Ballroom | Session 102: Keynote Address, <i>Targeting the Microbiome to Promote Health and End Cancer</i> | Jennifer A. Wargo, MD, MMSc The University of Texas MD Anderson Cancer Center |
| 9:45 AM | Potomac Ballroom | Session 103: Thomas Waldmann Memorial Plenary Session: Neuro-immunology as an Untapped Opportunity in Cancer Immunotherapy, <i>More Than Just a Symptom: Pain Sensation in Inflammation and Cancer</i> | Ulrich von Andrian, MD, PhD Harvard University |
| 2:30 PM | Maryland Ballroom AB | Session 106b: Microbiota and IO: Mode of Action and Clinical Relevance, <i>Subclinical Cholestasis, Gut Microbiota and Cancer Immunosurveillance</i> | Laurence Zitvogel, MD, PhD, FAIO Gustave Roussy |
| 2:35 PM | Maryland Ballroom CD | Session 106c: Immunoprevention / Immune Interception, <i>MUC1 Vaccine Targets Pre-Cancer: The Path to Primary Prevention</i> | Olivera Finn, PhD University of Pittsburgh |
| 4:40 PM | Maryland Ballroom CD | Session 107c: Immune Regulatory Subsets in Tumors, <i>Defining and Targeting B Cell Exhaustion in Human Tumors</i> | Tullia Bruno, PhD University of Pittsburgh |
| 4:55 PM | Cherry Blossom Ballroom | Session 107a: Age-Related Changes in Tumor Immune Microenvironment, <i>Neuro-Immune Interactions That Change With Age in Patients With Glioblastoma: Relevance to Immunotherapy</i> | Derek Wainwright, PhD Loyola University Chicago Stritch School of Medicine |
| 5:00 PM | Maryland Ballroom CD | Session 107c: Immune Regulatory Subsets in Tumors, <i>Local type 2 stromal-myeloid signalling axis drives progression and immunotherapy resistance of colorectal cancer metastasis</i> | Jesse Boumhella Icahn School of Medicine at Mount Sinai |

Saturday, November 8 | 12:30 pm, Cherry Blossom Ballroom

Session 205c: The Momentum and Future of Cancer Research Funding, Panel Discussion

Co-Chair: Ira Mellman, PhD
Parker Institute for Cancer Immunotherapy

Co-Chair: Miriam Merad, MD, PhD
Icahn School of Medicine at Mount Sinai

Sacha Gnjjatic, PhD
Icahn School of Medicine at Mount Sinai

Tyler Jacks, PhD
Koch Institute for Integrative Cancer Research at MIT

Catherine Wu, MD
Dana-Farber Cancer Institute

Alicia Zhou, PhD
Cancer Research Institute

Peter Marks, MD, PhD

Karen Knudsen, MBA, PhD
Parker Institute for Cancer Immunotherapy

SATURDAY, NOVEMBER 8

| TIME | LOCATION | SESSION & TALK TITLE | SPEAKER |
|--|-------------------------|--|--|
| 8:10 AM | Potomac Ballroom | Session 202: Richard V. Smalley Memorial Award and Lectureship, <i>The Coming Renaissance of Cancer Immunotherapy</i> | Ira Mellman, PhD, FAACR, FAIO Parker Institute for Cancer Immunotherapy / Medici Therapeutics |
| <p>12:30 pm, Cherry Blossom Ballroom</p> <p>Session 205c: The Momentum and Future of Cancer Research Funding, Panel Discussion (see panel listing on front page)</p> | | | |
| 12:38 PM | Maryland Ballroom CD | Session 205b: Rapid Oral Abstract Session - Clinical, (519) <i>GDFATHER-01 Trial Longterm Follow-up: GDF-15 Neutralization Combined with Nivolumab can Enable Deep, Longterm Remission in Heavily Pretreated, anti-PD1/-L1 Relapsed/Refractory Major Solid Tumor Types</i> | Ignacio Melero, MD, PhD Clinica Universidad de Navarra and Cima and University of Oxford |
| 3:30 PM | Cherry Blossom Level | Session 207c: The Dark Genome: Making Cryptic Epitopes Actionable, <i>Introduction</i> | Bernard A. Fox, PhD Earle A. Chiles Research Institute, Providence Cancer Institute |
| 3:35 PM | Potomac Ballroom | Session 207a: Cellular Therapies for Solid Tumors, Cell Therapies beyond CAR T Cells, <i>From Complexity to Therapy: Targeting Tumor-Promoting Lipid Macrophages with CAR-Monocytes</i> | Jennifer L. Guerriero, PhD Brigham and Women's Hospital |
| 3:35 PM | Maryland Ballroom AB | Session 207b: Immunometabolism, <i>Cytoskeletal Control of T Cell Metabolic Fitness in Cancer</i> | Juan R. Cubillos-Ruiz, PhD Cornell University |
| 3:35 PM | Cherry Blossom Ballroom | Session 207c: The Dark Genome: Making Cryptic Epitopes Actionable, <i>The Dark Genome as a Source of Candidate Tumor Antigens</i> | Catherine J. Wu, MD Dana Farber Cancer Institute |
| 3:55 PM | Maryland Ballroom AB | Session 207b: Immunometabolism, <i>Metabolic Liabilities in the Generation of Cellular Therapies for Cancer</i> | Greg Delgoffe, PhD University of Pittsburgh |
| 3:55 PM | Cherry Blossom Level | Session 207c: The Dark Genome: Making Cryptic Epitopes Actionable, <i>Targeting the Dark Proteome Using TCR Gene Therapy</i> | Christopher Klebanoff, MD Memorial Sloan Kettering Cancer Center |

SUNDAY, NOVEMBER 9

| TIME | LOCATION | SESSION & TALK TITLE | SPEAKER |
|----------|------------------|---|---|
| 8:00 AM | Potomac Ballroom | Session 300: Organizer Welcome | Miriam Merad, MD, PhD, FAIO Icahn School of Medicine at Mount Sinai |
| 8:40 AM | Potomac Ballroom | Session 301: Presidential Session, <i>Expert Discussant</i> | Miriam Merad, MD, PhD, FAIO Icahn School of Medicine at Mount Sinai |
| 9:20 AM | Potomac Ballroom | Session 301: Presidential Session, <i>Expert Discussant</i> | Roberta Zappasodi, PhD Weill Cornell Medicine |
| 10:30 AM | Potomac Ballroom | Session 302: Beyond Cytotoxic Chemotherapy: The Next Generation of ADCs for Immune Modulation, <i>More Than Cell Killers: Mechanistic Insights into ADC Payload Classes and Immune Engagement</i> | Margaret K. Callahan, MD, PhD University of Connecticut School of Medicine |